KURA
- Kura Oncology, Inc.
()
Overview
Company Summary
Kura Oncology, Inc. (KURA) is a biopharmaceutical company focused on the development of precision medicines for the treatment of cancer. The company's primary objective is to address the unmet medical needs of patients by targeting specific genetic alterations that drive the growth and progression of cancer.
Kura Oncology employs a precision medicine approach, which involves identifying and understanding the underlying genetic mutations or alterations that are unique to each patient's tumor. By targeting these specific genetic drivers, the company aims to develop therapies that have the potential to deliver more effective and personalized treatment options.
The company's pipeline includes several investigational drugs at various stages of development. Kura Oncology focuses on developing small molecule inhibitors that selectively target specific cancer-associated mutations, thereby inhibiting the growth and proliferation of cancer cells while minimizing harm to healthy cells.
One of Kura Oncology's lead product candidates is tipifarnib, an oral, investigational drug currently being evaluated in multiple Phase 2 clinical trials across various hematologic and solid tumor indications. Tipifarnib targets a protein called farnesyl transferase, which plays a crucial role in the signaling pathways of certain cancer-causing proteins. By inhibiting this protein, tipifarnib has the potential to disrupt the growth and survival of cancer cells.
In addition to tipifarnib, Kura Oncology has other programs aimed at developing therapies that target specific genetic alterations associated with various types of cancer. The company collaborates with academic institutions, research organizations, and biotechnology companies to further enhance its understanding of cancer biology and expand its drug development efforts.
Overall, Kura Oncology is committed to advancing precision medicine in cancer treatment by developing innovative therapies that specifically target the genetic alterations driving tumor growth, with the ultimate goal of improving patient outcomes and quality of life.